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Recent evidence suggests that inadequate hydration of airway surfaces
is a commonmechanism in the pathogenesis of airwaymucus obstruc-
tion. Inhaled hypertonic saline (HS) induces osmotic water flux, im-
proving hydration of airway surfaces. However, trials in patients with
obstructive lung diseases are limited. The aim of this study was to
investigateeffectsofHSonmucusobstructionandairwayinflammation
in theprevention and treatment of obstructive lungdisease in vivo.We,
therefore, used the b-epithelial Na1 channel (bENaC)–overexpressing
mouse as a model of chronic obstructive lung disease and determined
effects of preventive and late therapy with 3% HS and 7% HS on pul-
monary mortality, airway mucus obstruction, and inflammation. We
found that preventive treatment with 3% HS and 7% HS improved
growth, reducedmortality, and reducedmucusobstruction inneonatal
bENaC-overexpressingmice. In adultbENaC-overexpressingmicewith
chronic lung disease, mucus obstruction was significantly reduced
by 7% HS, but not by 3% HS. Treatment with HS triggered airway
inflammation with elevated keratinocyte chemoattractant levels and
neutrophils in airways from wild-type mice, but reduced keratinocyte
chemoattractant in chronic neutrophilic inflammation in adult bENaC-
overexpressing mice. Our data demonstrate that airway surface rehy-
dration with HS provides an effective preventive and late therapy of
mucus obstruction with no consistent effects on inflammation in
chronic lung disease. These results suggest that, through mucokinetic
effects,HSmaybebeneficial forpatientswitha spectrumofobstructive
lung diseases, and that additional strategies are required for effective
treatment of associated airway inflammation.
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Airway surface dehydration caused by abnormal transport of ions
and fluid across airway epithelia due to mutations in the cystic fi-
brosis (CF) transmembrane conductance regulator (CFTR) gene is
an important disease mechanism, producing increased mucus con-
centration, reduced mucociliary clearance, and airway mucus ob-
struction in patients with CF (1–6). Recent results suggest that
relative dehydration of airway surfaces, either caused by reduced
availability of airway surface liquid due to dysregulated epithelial
ion transport, or increased mucin secretion triggered by airway
inflammation, generates an abnormally concentrated mucus that
impairs mucus clearance and produces airway mucus obstruc-
tion in a spectrum of other acute and chronic obstructive lung
diseases, including asthma and chronic obstructive pulmonary
disease (COPD) (7–12).
Evidence from these studies predicts that airway surface re-
hydration provides a rational therapeutic approach to restore
normal mucus concentrations and reduce mucus obstruction in
CF and potentially other mucostatic airway diseases. Therapeu-
tic strategies currently available in the clinic to clear mucus
(i.e., “mucokinetic agents”) are limited to hyperosmolar agents,
such as inhaled hypertonic saline (HS) and mannitol. These agents,
when inhaled, create osmotic gradients that draw water into the
airway lumen and produce dose-dependent, transient improve-
ments in airway surface liquid volume and mucociliary clearance
(13–16). In patients with CF, the prototypical osmolyte, HS, im-
proved mucus clearance and lung function after short-term inha-
lation (17). Furthermore, long-term inhalation of 7%HS produced
modest improvements in lung function and reduced pulmonary
exacerbations in patients older than 6 years (18). However, in
infants and younger children with CF, the assessment of therapeu-
tic benefits of HS has been hampered by the lack of established
clinical trial endpoints, and produced more mixed results. In this
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CLINICAL RELEVANCE
Airway mucus obstruction contributes significantly to the
morbidity and mortality of cystic fibrosis (CF) and other
chronic obstructive lung diseases. However, therapies to
clear mucus are limited, and their in vivo effects on airway
mucus obstruction unknown. This study demonstrates that
improving airway surface hydration with the osmotically
active inhaled hypertonic saline provides an effective mu-
cus clearance (mucokinetic) therapy in a murine disease
model, suggesting that hydration strategies may be bene-
ficial for the prevention and treatment of mucus obstruc-
tion in patients with CF and potentially other obstructive
lung diseases.
age group, HS had no effects on pulmonary exacerbations, but, in
substudies, had positive effects on FEV0.5 and lung clearance index
(19, 20).
Based on these mixed results, the therapeutic potential of in-
haled HS for the prevention and treatment of mucus obstruction
remains poorly defined. The dose–effect relationships between
the frequency of daily HS administration and FEV1 (17, 18),
and the mixed data in the Infant Study of Inhaled Saline in CF
(ISIS) (19), raise the question of whether the optimal dose of
deposited HS for efficacy has been defined. Moreover, previous
studies indicated that HS can induce airway inflammation (21–
25) in healthy individuals, consistent with dose-dependent off-
setting effects in the treatment of airway disease. However, the
interpretation of results from these clinical trials is hampered by
the lack of endpoints that directly measure dose-dependent effects
of HS on airway mucus obstruction and inflammation (17–19).
The aim of our study was, therefore, to measure the dose-
dependent effects of HS on airway mucus obstruction and inflam-
mation in vivo. To achieve this goal, we used the b-epithelial Na1
channel (bENaC)–overexpressing mouse as a model of chronic
mucostatic lung disease that shares key features with CF and
COPD (26–28), and determined the effects of preventive HS treat-
ment versus late HS intervention on growth, survival, airway mucus
obstruction, and airway inflammation. Furthermore, we compared
effects of different concentrations of HS (3 and 7%) on these
endpoints. Some of the results of these studies have been previ-
ously reported in the form of an abstract (29).
MATERIALS AND METHODS
Experimental Animals
All animal studies were approved by the Regierungspräsidium Karls-
ruhe, Germany. bENaC-overexpressing mice (line 6608) were bred to
C3H/HeN 3 C57BL/6N F1 wild-type mice to maintain the colony on
a mixed genetic background, and were identified by PCR as previously
described (26). Wild-type littermates served as control animals in all
experiments. Mice were housed in a specific pathogen-free animal fa-
cility and had free access to chow and water.
HS Treatment Studies
NaCl (10%; B. Braun Melsungen AG, Melsungen, Germany) was di-
luted with sterile distilled water (ddH2O) to obtain 3% HS or 7%
HS solutions. To test preventive effects of increasing doses of HS,
newborn bENaC-overexpressing mice and wild-type littermates were
treated with intranasal instillation of 3% HS or 7% HS (1 ml/g body
weight, three times per d) or equal volumes of vehicle (ddH2O) alone
from the first day of life for a period of 2 weeks. To test effects of HS in
chronic obstructive lung disease, 4-week-old adult bENaC-overexpressing
mice and wild-type littermates were treated with intratracheal instillation
of 3% HS or 7% HS (1 ml/g body weight, three times per d) or equal
volumes of vehicle (ddH2O) alone for a period of 2 weeks. During HS
treatment, growth and survival were monitored. At 12 hours after the last
treatment, bronchoalveolar lavage (BAL) was performed and lungs were
removed for histology and morphometry, as previously described (30).
Furthermore, adult wild-type mice were treated with intratracheal instil-
lation of 7% HS or 18% mannitol (D-Mannitol [Sigma-Aldrich Co., St.
Louis, MO] dissolved in ddH2O) for a period of 3 days, and BAL was
performed 12 hours after the last treatment and assessed for signs of
airway inflammation. All endpoint studies were performed by investiga-
tors blinded to genotype and treatment of the mice.
BAL Cell Counts and Cytokine Measurements
Mice were deeply anesthetized by intraperitoneal injection with
ketamine/xylazine (120 mg/kg and 16 mg/kg), and the right lobes
were lavaged with PBS. BAL cell counts were determined on cyto-
spin preparations, as previously described (27). Cytokine concen-
trations were measured in cell-free BAL fluid, stored at 2808C, by
ELISA (R&D Systems, Minneapolis, MN), according to manufac-
turer’s instructions.
Histology and Airway Morphometry
The left lobe was immersion fixed in 4% formalin, paraffin embedded
and sectioned at the level of the proximal intrapulmonary main axial
airway near the hilus and the distal intrapulmonary main axial airway
(27). Sections were cut at 5 mm and stained with Alcian blue periodic
acid-Schiff. Airway mucus obstruction was assessed by determining
mucus volume density on images of airway sections taken with an
Olympus IX-71 microscope (Olympus, Hamburg, Germany), as previ-
ously described (27). Images were analyzed using Cell^F imaging soft-
ware (OSIS, Münster, Germany), and mucus volume density, obtained
for each experimental group, was normalized to vehicle-treated wild-
type mice.
Statistical Analysis
Data were analyzed with SigmaStat version 3.5 (Systat Software, Erk-
rath, Germany) and are reported as means (6SEM). Statistical analyses
were performed using unpaired Student’s t test, Mann-Whitney rank
sum test, and Kaplan-Meier survival analysis, as appropriate, and a P
value less than 0.05 was accepted to indicate statistical significance.
RESULTS
Preventive HS Therapy Reduces Mortality and Growth
Retardation Associated with Lung Disease in
bENaC-Overexpressing Mice
Airway surface dehydration in bENaC-overexpressing mice caused
early onset mucus obstruction associated with substantial pul-
monary mortality and reduced weight gain in the first weeks of
life (Figure 1) (26, 27). To determine if preventive therapy with HS
has benefits on growth and survival, and if therapeutic effects are
dose dependent, we treated bENaC-overexpressing mice and wild-
type littermates from the first day of life with intranasal instillation
(1 ml/g body weight) of 3% HS, 7% HS, or vehicle alone (ddH2O),
three times per day for a period of 2 weeks. Vehicle-treated
bENaC-overexpressing mice showed a mortality rate of roughly
60% and growth retardation with a reduction in body weight of
approximately 10% (Figure 1) at the age of 2 weeks. Preventive
treatment with both 3% HS and 7% HS reduced pulmonary mor-
tality significantly in bENaC-overexpressing mice (Figures 1A and
1B). Furthermore, impaired growth associated with obstructive
lung disease in surviving bENaC-overexpressing mice was re-
stored by treatment with both concentrations of HS (Figures
1C and 1D). In wild-type mice, HS treatment was well toler-
ated and had no effect on growth or survival (Figures 1A–1D).
These results suggest that preventive HS therapy, at concen-
trations ranging from 3 to 7%, reduced mucus obstruction–
induced mortality in bENaC-overexpressing mice.
Preventive HS Therapy Reduces Airway Mucus Obstruction
in bENaC-Overexpressing Mice
To evaluate effects of preventive HS treatment on airway mucus
obstruction more directly, we next assessed the mucus content in
distal and proximal airways in bENaC-overexpressing mice and
wild-type littermates after 2 weeks of preventive therapy with
either 3% HS, 7% HS, or vehicle alone. Morphometric analyses
of lung sections from vehicle-treated bENaC-overexpressing
mice exhibited mucus obstruction in proximal and distal airways
(Figures 2A–2C). Treatment with HS had no effect on mucus
content in wild-type mice. Both 3% HS and 7% HS resulted in
a significant reduction of airway mucus in distal airways of
bENaC-overexpressing mice (Figures 2A and 2C). Furthermore,
preventive treatment with 7%HS, but not 3% HS, reduced mucus
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to near-normal levels in proximal airways of bENaC-overexpressing
mice (Figure 2B). These results demonstrate that preventive HS has
potent mucokinetic effects in the early pathogenesis of chronic ob-
structive lung disease in bENaC-overexpressing mice, and suggest
that 7% HS may be more effective for clearance of mucus from
central airways.
Treatment with 7% HS Is Required to Reduce Airway
Mucus Obstruction in Adult bENaC-Overexpressing
Mice with Chronic Obstructive Lung Disease
Adult bENaC-overexpressing mice exhibit characteristic fea-
tures of chronic obstructive lung disease in humans, including
chronic airway inflammation with goblet cell metaplasia and
mucus hypersecretion (26, 27). To evaluate effects of HS ther-
apy on mucus obstruction in chronic lung disease, we extended
our studies to adult bENaC-overexpressing mice. As for the pre-
ventive HS studies, adult bENaC-overexpressing mice and wild-
type littermates were treated with 3% HS, 7% HS, or vehicle
alone for a period of 2 weeks. Similar to the preventive studies,
HS had no effect on mucus content in wild-type mice, and vehicle-
treated bENaC-overexpressing mice showed mucus obstruction in
proximal and distal main axial airways (Figure 3). Late therapy
with 3% HS failed to reduce airway mucus obstruction in small
(or large) airways in adult bENaC-overexpressing mice with
chronic lung disease (Figure 3). However, when the concentration
Figure 1. Preventive treatment with 3% and 7% hypertonic
saline (HS) reduces mortality and improves growth in neona-
tal b-epithelial Na1 channel (bENaC)–overexpressing mice.
(A and B) Survival curves for bENaC-overexpressing (bENaC-
Tg) mice and wild-type (WT) littermates treated with 3% HS
(A), 7% HS (B), or vehicle alone, administered from the first
day of life for a period of 2 weeks. (C and D) Body weight of
bENaC-overexpressing mice and WT littermates on the last
day of the 2-week treatment with 3% HS (C), 7% HS (D), or
vehicle alone (n ¼ 17–65 mice per group). *P , 0.05
and **P , 0.001 compared with vehicle-treated WT
mice; yP , 0.05 and zP , 0.001 compared with vehicle-
treated bENaC-overexpressing mice.
Figure 2. Preventive treatment with 3%
and 7% HS reduces mucus obstruction
in neonatal bENaC-overexpressing mice.
(A) Morphology of distal main axial air-
ways from neonatal bENaC-overexpress-
ing (bENaC-Tg) mice and WT littermates
after 2 weeks of preventive treatment
with 3% HS, 7% HS, or vehicle alone. Sec-
tions were stained with Alcian blue peri-
odic acid-Schiff (AB-PAS) to determine
the presence of airway mucus. Scale bars,
100 mm. (B and C) Airway mucus content
was determined by measuring the volume
density of AB-PAS–positive material in
proximal (B) and distal (C) main axial air-
ways (n ¼ 14–52 mice for each group).
*P< 0.01 and **P, 0.001 compared with
vehicle-treated wild-type mice; yP , 0.05
compared with vehicle-treated bENaC-
overexpressing mice.
412 AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY VOL 49 2013
was increased to 7% HS, therapeutic effects were observed and
airway mucus content was reduced to near-normal levels in both
proximal and distal airway regions in bENaC-overexpressing mice
(Figure 3). These data show that 7% HS is an effective mucoki-
netic agent in chronic lung disease in vivo.
HS and Airway Inflammation in Wild-Type and
bENaC-Overexpressing Mice
Airway inflammation is an important feature of chronic obstructive
lung disease that can cause progressive damage and remodeling of
the lung. Because of contrasting studies reporting proinflammatory
effects of HS in human airway epithelial cells in vitro (21, 22) and in
healthy individuals in vivo (23–25), versus studies reporting anti-
inflammatory effects in patients with CF in vivo (31), we evaluated
the effects of preventive and late therapy with 3% HS and 7% HS
on BAL cell counts and levels of keratinocyte chemoattractant
(KC; CXCL1), the mouse homolog of human IL-8, in wild-type
and bENaC-overexpressing mice (Figures 4 and 5).
As previously reported and consistent with a T helper type 2–
biased immune system in the neonatal period (27, 32), BAL from
2-week-old wild-type mice contained substantial numbers of eosi-
nophils. bENaC-overexpressing mice were characterized by in-
creased inflammation, as evidenced by an increase in eosinophils
and neutrophils in BAL (Figures 4A, 4D, and 4E). In the preven-
tive HS studies, both 3%HS and 7%HS triggered a mild and dose-
dependent inflammatory response, with increased macrophages,
eosinophils, and neutrophils in BAL from HS-treated compared
with vehicle-treated wild-type mice (Figures 4A–4E). Furthermore,
KC levels were slightly but significantly (z2-fold) higher in wild-
type mice treated with 7% HS compared with vehicle-treated
control animals (Figure 4F). In bENaC-overexpressing mice, pre-
ventive therapy with 3%HS and 7%HS had no effects on elevated
BAL macrophages and eosinophils (Figures 4A–4D). Treatment
with 7%HS, but not 3%HS, increased BAL neutrophils compared
with vehicle-treated bENaC-overexpressing littermates (Figure
4E). Lymphocyte numbers in BAL were low, and did not differ
between experimental groups (data not shown). KC levels were
substantially increased in BAL fluid from vehicle-treated bENaC-
overexpressing mice compared with wild-type littermates, and
preventive HS had no effect on elevated KC levels in bENaC-
overexpressing mice (Figure 4F).
In the late intervention studies, treatment of wild-type mice with
3% HS and 7% HS had no effect on BAL macrophages and eosi-
nophils, but both doses induced neutrophilia (Figures 5A–5D). Fur-
thermore, HS also caused a dose-dependent increase in KC levels in
wild-type mice (Figure 5E). In adult bENaC-overexpressing mice,
late therapy with 3% HS and 7% HS reduced the low-grade eosin-
ophilia, but had no effects on BAL macrophages and neutrophils
that dominate chronic airway inflammation at this age (Figures 5A–
5D) (27). Neutrophilic inflammation was associated with increased
KC levels in BAL fluid from vehicle-treated bENaC-overexpressing
mice. Late treatment with 7% HS, but not 3% HS, reduced KC
levels significantly in bENaC-overexpressing mice.
To determine if the proinflammatory response to HS therapy
was specific for HS or mediated by hypertonicity as previously de-
scribed for cultured airway epithelial cells (21, 22), we compared
effects of 7% HS and 18% mannitol on airway inflammation in
adult wild-type mice. Similar to 7% HS, treatment with 18% man-
nitol caused a significant increase in neutrophils and increased KC
levels in wild-type mice (see Figure E1 in the online supplement).
These results show that HS therapy causes dose-dependent inflam-
mation in healthy airways, and indicate that this proinflammatory
effect was mediated by an osmotic stress response. In bENaC-
overexpressing mice with chronic lung disease, HS treatment did
not aggravate chronic airway inflammation, but was associated
with a dose-dependent reduction of KC levels in the lung.
DISCUSSION
Airway mucus obstruction causes airflow limitation and is a nidus
for inflammation and infection in CF and other chronic obstructive
Figure 3. Therapeutic effects of late HS
treatment on mucus obstruction in adult
bENaC-overexpressing mice with chronic
lung disease are dose dependent. (A) Mor-
phology of distal main axial airways from 6-
week-old bENaC-overexpressing (bENaC-Tg)
mice and WT littermates after 2 weeks of
treatment with 3% HS, 7% HS or vehicle
alone. Sections were stained with Alcian
blue periodic acid-Schiff (AB-PAS) to de-
termine the presence of airway mucus.
Scale bars, 100 mm. (B and C) Airway mu-
cus content was determined bymeasuring
the volume density of AB-PAS–positive
material in proximal (B) and distal (C) main
axial airways (n ¼ 24–35 mice for each
group). *P , 0.05 and **P , 0.001 com-
pared with vehicle-treated wild-type mice;
yP, 0.01 and zP, 0.001 compared with
vehicle-treated bENaC-overexpressing mice.
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lung diseases (6, 12, 32, 33). However, currently available ther-
apies to clear mucus are limited, and the assessment of their
effectiveness relies on surrogate endpoints, such as lung func-
tion and pulmonary exacerbations (17, 18, 34, 35). Conse-
quently, their effects on clearing obstructive mucus from
airways in vivo remain unknown. In the present study, we used
the bENaC-overexpressing mouse as a model of chronic obstruc-
tive lung disease that shares key features with CF and COPD (26–
28) to determine therapeutic effects of HS in the prevention and
treatment of mucus obstruction and associated airway inflamma-
tion. Our results show, for the first time, that inhaled HS is effec-
tive as a preventive treatment as well as a rescue therapy in
chronic obstructive lung disease in vivo (Figures 1–3). Previous
studies in cultured human primary airway epithelia demonstrated
that HS, similar to nonionic osmolytes, produces a transient in-
crease in airway surface hydration (13, 17). Although we did not
compare HS with other osmotic agents, such as mannitol, in our
study, we predict that therapeutic benefits of HS in mobilizing
mucus in bENaC-overexpressing mice were mediated by this
mechanism of action.
Our studies in neonatal mice show that preventive HS treat-
ment reduced airway mucus content to near-normal levels, and
that this therapeutic effect was associated with significant reduc-
tion in pulmonary mortality and growth retardation in bENaC-
overexpressing mice (Figures 1 and 2). In a previous study, we
demonstrated that preventive inhibition of epithelial Na1 ab-
sorption with the ENaC blocker amiloride is also an effective
approach to reduce mucus obstruction and mortality in this
murine disease model (30). However, although early diagnosis
has become feasible for a substantial number of patients with
CF by widespread implementation of newborn screening, clin-
ical testing of preventive amiloride inhalation therapy has been
impeded by lack of toxicity data for amiloride in neonatal de-
velopment and regulatory requirements for clinical testing of
pharmacological compounds in infants (36). The potential and
requirement for preventive mucokinetic therapies for CF is
highlighted by recent studies demonstrating that signs of ob-
structive airway disease, such as air trapping and bronchiectasis,
are frequently present on chest CT and lung function testing in
the first months of life, even in asymptomatic infants diagnosed
by CF newborn screening (37–40). In a recent randomized con-
trolled trial (ISIS) in infants and children younger than 6 years
with CF, inhaled HS did not reduce the rate of pulmonary exac-
erbations. However, substudy outcome measures that may reflect
airway mucus obstruction (e.g., FEV0.5 and lung clearance index)
suggested benefit from HS (19, 20). Our data from neonatal
bENaC-overexpressing mice demonstrate directly that airway sur-
face rehydration with HS is effective in preventing the develop-
ment of mucus obstruction in vivo. These results, together with
safety data in infants and young children (19, 41), suggest inhaled
HS as an inexpensive and safe preventive treatment for infants
with CF. Consequently, the potential benefits of this preventive
strategy should be further explored in clinical trials that include
morphological and functional surrogate endpoints that are more
sensitive and more specific in capturing treatment responses in
early obstructive airways disease (36, 38–40, 42, 43).
Figure 4. Preventive treatment with 3%
and 7% HS triggers airway inflammation.
(A–F) Neonatal bENaC-overexpressing
(bENaC-Tg) mice and WT littermates
were treated with 3% HS, 7% HS, or ve-
hicle alone from birth for a period of 2
weeks. (A) Effects of preventive treatment
on cellularity of cytospin preparations
(stained with May-Grünwald-Giemsa;
neutrophilic and eosinophilic granulo-
cytes are indicated by arrows; scale
bars, 20 mm), and summary of effects
on total cells (B), macrophages (C ),
eosinophils (D), neutrophils (E ), and
keratinocyte chemoattractant (KC)
concentrations (F ) in bronchoalveolar
lavage (BAL) (n ¼ 13–55 mice for each
group). *P , 0.01 and **P , 0.001
compared with vehicle-treated wild-
type mice; yP , 0.05 and zP , 0.001
compared with vehicle-treated mice of
the same genotype.
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In a previous study, we also demonstrated that treatment with
amiloride, probably because of limited potency and short half-
life on airway surfaces, was ineffective when treatment was
started after the onset of lung disease in bENaC-overexpressing
mice (30). In contrast, 7% HS exhibited significant mucokinetic
effects in adult bENaC-overexpressing mice with chronic lung
disease (Figure 3). However, treatment with 3% HS was ineffec-
tive, indicating that higher osmotic gradients were required for
sufficient mucus hydration and clearance in the context of chronic
airway disease associated with goblet cell metaplasia and mucus
hypersecretion (Figure 3) (27). Our observations, that mucoki-
netic effects of HS in chronic lung disease were dose-dependent,
are consistent with results from human studies, where more inten-
sive inhalation of 7% HS (i.e., 5 ml four times daily) was more
effective in improving lung function in patients with established CF
lung disease than a less-intensive inhalation regimen of 4 ml twice
daily (17, 18). These results indicate that therapeutic benefits of
7% HS may be enhanced by increasing its overall dose via more
frequent inhalations in patients with CF with chronic lung disease.
Interestingly, evidence from recent biophysical studies suggests
that airway surface dehydration and increased mucus concentra-
tion may not only be critical in CF, but also in the pathogenesis of
other airway diseases (7, 44). These studies demonstrate that an
increase in mucus concentration leads to an increase of the os-
motic modulus of the mucus gel that covers airway surfaces.
Above a critical threshold, the osmotic modulus of the mucus
layer exceeds the osmotic modulus of the subjacent periciliary
layer, causing compression of the periciliary layer and cilia,
and mucociliary dysfunction (7). Because increased mucus
concentration cannot only result from reduced amounts of air-
way surface fluid due to primary defects in epithelial ion trans-
port as in CF (1, 2, 6), but also from an increased amount of
secreted mucins triggered by airway inflammation and infec-
tion (11, 12, 45), the study by Button and colleagues (7) sup-
ports the concept that insufficient hydration of airway surfaces
is a common disease mechanism contributing to mucociliary
dysfunction and mucus obstruction in a broad spectrum of
obstructive lung diseases (44). This concept is supported by
the airway phenotype of the bENaC-overexpressing mouse, which
develops spontaneous mucus obstruction caused by constitutive
hyperabsorption of airway surface fluid due to an increased activ-
ity of ENaC (9, 26, 27). The concept is also supported by the
phenotype of mice lacking the SLC26A9 Cl2 channel, which show
normal ion transport and airway morphology under physiological
conditions, but develop airwaymucus obstruction due to a reduced
capacity to increase Cl2 and fluid secretion in parallel to mucin
hypersecretion in allergic airway disease (8, 46).
In this context, the results from our studies in bENaC-
overexpressing mice, demonstrating that HS has potent mucoki-
netic effects in vivo, provide a proof of concept that airway surface
rehydration may be an effective therapy in a spectrum of acute and
chronic obstructive airway diseases beyond CF. So far, this notion
is supported by a limited number of clinical trials demonstrating
that nebulized HS reduces the length of hospital stay and improves
Figure 5. Late treatment with 3% and
7% HS causes neutrophilic inflammation
in WT mice, but does not increase airway
neutrophilia in adult bENaC-overexpressing
mice with chronic lung disease. (A–E) Adult
bENaC-overexpressing mice (bENaC-Tg)
and WT littermates were treated with 3%
HS, 7% HS, or vehicle alone from birth for
a period of 2 weeks. Summary of effects on
total cells (A), macrophages (B), eosinophils
(C), neutrophils (D), and KC concentrations
(E) in BAL (n ¼ 24–35 mice for each
group). *P , 0.01 and **P < 0.001 com-
pared with vehicle-treated wild-type
mice; yP , 0.05 and zP , 0.001 com-
pared with vehicle-treated mice of the
same genotype.
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clinical symptoms in infants with acute viral bronchiolitis (47), and
improves lung function and quality of life in patients with non-CF
bronchiectasis (48). Of note, therapeutic effects of HS were supe-
rior to treatment with bronchodilators or anti-inflammatory ther-
apy with glucocorticoids in acute viral bronchiolitis (47, 49, 50).
However, further clinical trials are required to determine the ther-
apeutic potential of rehydration therapies in common chronic lung
diseases, such as asthma and COPD, including patients with sub-
phenotypes that are accompanied by substantial mucus obstruction
and respond poorly to bronchodilators and anti-inflammatory drugs
(12, 33).
Consistent with previous in vitro studies demonstrating that
hyperosmolarity induces production of IL-8 in human airway
epithelial cells (21, 22), treatment with HS induced a dose-
dependent elevation of KC, the mouse homolog of IL-8, in
BAL fluid from neonatal and adult wild-type mice (Figures 4
and 5). Increased KC concentrations were associated with induc-
tion of mild neutrophilic airway inflammation in HS-treated wild-
type mice. Similar responses with elevated KC and neutrophils in
BAL were observed when mice were treated with mannitol, dem-
onstrating that this proinflammatory response was indeed induced
by hyperosmolarity (Figure E1). Repeated inhalation of HS has
also been shown to induce transient neutrophilic airway inflam-
mation due to mediator release from epithelial and/or mast cells
in healthy individuals (23–25). Taken together, these results sug-
gest that proinflammatory effects triggered by hypertonic stress
may limit the therapeutic benefits of inhaled HS when used in
patients before the onset of airway inflammation. Importantly, our
studies in adult bENaC-overexpressing mice demonstrate that HS
treatment did not aggravate chronic airway inflammation associ-
ated with chronic mucus obstruction (Figure 5). In this context,
neither 3% HS nor 7% HS increased KC expression or airway
neutrophilia, supporting the safety of inhaled HS in the treatment
of chronic obstructive lung disease. Of note, KC levels were sig-
nificantly reduced by 7%HS in the context of chronic lung disease
in adult bENaC-overexpressing mice (Figure 5). These results are
consistent with a recent study showing that inhaled HS decreased
IL-8 in the sputum of patients with CF (31). This study demon-
strated that HS disrupts the interaction between IL-8 and protec-
tive glycosaminoglycans, rendering IL-8 susceptible to proteolytic
degradation that may result in a decrease in neutrophil chemo-
taxis, and thus limit neutrophilic inflammation in chronic CF lung
disease (16, 31).
In summary, our results suggest that airway surface rehydration
by inhalation of the osmotically active agent HS constitutes an ef-
fective rehydration strategy for the prevention and treatment of
mucus obstruction in CF and, potentially, other obstructive lung
diseases. Limited anti-inflammatory effects of HS suggest that ad-
ditional anti-inflammatory strategies are necessary for effective
treatment of airway inflammation associated with mucus obstruc-
tion in chronic obstructive lung diseases.
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